An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors-Reference-Cited by-同舟云学术

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

Published:2017-10-04 Issue:410 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ishiguro Takahiro¹^ORCID,Sano Yuji²,Komatsu Shun-ichiro³,Kamata-Sakurai Mika³^ORCID,Kaneko Akihisa³^ORCID,Kinoshita Yasuko²,Shiraiwa Hirotake³,Azuma Yumiko²,Tsunenari Toshiaki²,Kayukawa Yoko²,Sonobe Yukiko²,Ono Natsuki³,Sakata Kiyoaki²,Fujii Toshihiko²,Miyazaki Yoko²,Noguchi Mizuho²,Endo Mika²,Harada Asako³,Frings Werner³^ORCID,Fujii Etsuko²,Nanba Eitaro³^ORCID,Narita Atsushi³,Sakamoto Akihisa³,Wakabayashi Tetsuya³^ORCID,Konishi Hiroko³,Segawa Hiroaki³,Igawa Tomoyuki³^ORCID,Tsushima Takashi²,Mutoh Hironori²^ORCID,Nishito Yukari²^ORCID,Takahashi Mina²,Stewart Lorraine⁴^ORCID,ElGabry Ehab⁴,Kawabe Yoshiki²³^ORCID,Ishigai Masaki³,Chiba Shuichi³^ORCID,Aoki Masahiro²^ORCID,Hattori Kunihiro²,Nezu Junichi⁵^ORCID

Affiliation:

1. Translational Clinical Research Division, Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku, Tokyo 103-8324, Japan.

2. Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan.

3. Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.

4. Companion Diagnostics Pharma Services, Ventana Medical Systems Inc., 1910 E Innovation Parkway, Tucson, AZ 85755, USA.

5. Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, Synapse 138623, Singapore.

Abstract

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody (ERY974) is a promising therapeutic agent for solid tumors.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference53 articles.

1. Immune Checkpoint Blockade in Cancer Therapy

2. Immune checkpoint inhibitors: Therapeutic advances in melanoma;Márquez-Rodas I.;Ann. Transl. Med.,2015

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

5. Neoantigens in cancer immunotherapy

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer;Advanced Science;2024-09-05

2. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

3. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma;Biochemistry and Biophysics Reports;2024-09

4. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia;Cellular and Molecular Life Sciences;2024-08-28

5. Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies;Frontiers in Bioscience-Landmark;2024-07-24